What You Must Know About Bioasis Technologies Inc.'s (CVE:BTI) Beta Value

Anyone researching Bioasis Technologies Inc. (CVE:BTI) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said 'volatility is far from synonymous with risk' in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Check out our latest analysis for Bioasis Technologies

Advertisement

What does BTI's beta value mean to investors?

With a beta of 0.94, (which is quite close to 1) the share price of Bioasis Technologies has historically been about as voltile as the broader market. While history does not always repeat, this may indicate that the stock price will continue to be exposed to market risk, albeit not overly so. Beta is worth considering, but it's also important to consider whether Bioasis Technologies is growing earnings and revenue. You can take a look for yourself, below.

TSXV:BTI Income Statement, March 13th 2019
TSXV:BTI Income Statement, March 13th 2019

Does BTI's size influence the expected beta?

With a market capitalisation of CA$21m, Bioasis Technologies is a very small company by global standards. It is quite likely to be unknown to most investors. It doesn't take much money to really move the share price of a company as small as this one. That makes it somewhat unusual that it has a beta value so close to the overall market.

What this means for you:

Since Bioasis Technologies has a beta close to one, it will probably show a positive return when the market is moving up, based on history. If you're trying to generate better returns than the market, it would be worth thinking about other metrics such as cashflows, dividends and revenue growth might be a more useful guide to the future. In order to fully understand whether BTI is a good investment for you, we also need to consider important company-specific fundamentals such as Bioasis Technologies’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Financial Health: Are BTI’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  2. Past Track Record: Has BTI been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of BTI's historicals for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About TSXV:BTI.H

Bioasis Technologies

A development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.

Low with weak fundamentals.

Advertisement

Weekly Picks

VA
valuebull
GOAI logo
valuebull on Eva Live ·

Is this the AI replacing marketing professionals?

Fair Value:US$7.4346.7% undervalued
12 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
ZA
PME logo
ZayaanS on Pro Medicus ·

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

Fair Value:AU$196.7841.0% undervalued
23 users have followed this narrative
4 users have commented on this narrative
17 users have liked this narrative
ST
WBD logo
SteveGruber on Warner Bros. Discovery ·

The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery  

Fair Value:US$18.1753.8% overvalued
4 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
PD
VRT logo
pdixit1 on Vertiv Holdings Co ·

The Infrastructure AI Cannot Be Built Without

Fair Value:US$408.6438.5% undervalued
27 users have followed this narrative
3 users have commented on this narrative
13 users have liked this narrative

Updated Narratives

VE
Vestra
KRYS logo
Vestra on Krystal Biotech ·

Krystal Biotech, Inc. (KRYS): The Gene Therapy Trailblazer – Scaling Vyjuvek and Pulmonary Pipelines.

Fair Value:US$371.2528.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
CEG logo
Vestra on Constellation Energy ·

Constellation Energy Corp (CEG): The Nuclear Powerhouse – Anchoring the AI Grid in 2026.

Fair Value:US$456.329.2% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
MDT logo
Vestra on Medtronic ·

Medtronic PLC (MDT): The Medical Tech Vanguard – Powering Growth Through Innovation in 2026.

Fair Value:US$111.7414.4% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.888.0% undervalued
65 users have followed this narrative
5 users have commented on this narrative
28 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59632.0% undervalued
1298 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.376.7% undervalued
48 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative